A Study to Evaluate the Safety and Tolerability of RO7296682 in Participants With Advanced Solid Tumours.

Official Title

An Open-label, Multicentre Phase 1 Study to Evaluate Safety, Tolerability, PK (Pharmacokinetics)/PD (Pharmacodynamics) of RO7296682, a T-regulatory Cell Depleting Antibody in Participants With Advanced and/or Metastatic Solid Tumours.

Summary:

This study will evaluate the safety and tolerability of RO7296682 in participants with advanced solid tumours.

Trial Description

Primary Outcome:

  • Percentage of Participants with Adverse Events
  • Percentage of Participants with Dose-Limiting Toxicities (DLTs)
Secondary Outcome:
  • Objective Response Rate (ORR)
  • Disease Control Rate (DCR)
  • Duration of Response (DOR)
  • Progression-Free Survival (PFS)
  • Area under the curve (AUC) of RO7296682
  • Minimum Concentration (Cmin) of RO7296682
  • Maximum Concentration (Cmax) of RO7296682
  • Clearance (CL) of RO7296682
  • Volume of distribution at steady-state conditions (Vss) of RO7296682
  • Half-life (t~1/2) of RO7296682
  • Time of maximum concentration (Tmax) of RO7296682
  • Incidence and titer of Anti-Drug Antibodies (ADA) during the study relative to the prevalence of ADA at baseline
  • Treatment-induced changes in Treg levels in blood and/or tumour as compared to baseline
  • Treatment-induced changes in Treg/Teff (T-regulatory cell; T-effector cell) ratio in blood and/or tumour as compared to baseline
A Phase 1, open-label, dose-escalation study designed to evaluate the safety and tolerability of RO7296682 in participants with advanced and/or metastatic solid tumours. RO7296682 will be administered by intravenous (IV) infusion every 3 weeks. This entry-into-human study is divided into a dose-escalation stage (Part A) and a dose expansion stage (Part B).

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society